VanEck Biotech ETF
BBH
59 hedge funds and large institutions have $153M invested in VanEck Biotech ETF in 2014 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 17 reducing their positions, and 7 closing their positions.
139% more call options, than puts
Call options by funds: $6.69M | Put options by funds: $2.79M
35% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 17
24% more capital invested
Capital invested by funds: $123M → $153M (+$29.8M)
4.3% more ownership
Funds ownership: 24.59% → 28.89% (+4.3%)
0% more funds holding
Funds holding: 59 → 59 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$16.2M |
| 2 |
Morgan Stanley
New York
|
+$1.6M |
| 3 |
SG Americas Securities
New York
|
+$1.24M |
| 4 |
U
UBS
Zurich,
Switzerland
|
+$1.18M |
| 5 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$1.42M |
| 2 |
AHS
Aspiriant Holdings S3
Los Angeles,
California
|
-$1.29M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.19M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.07M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$975K |
BBH Hedge Fund Activity: Q3 2014 in Review
59 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q3 2014, worth a combined $153M — up 24% from $123M a quarter earlier.
Fund positioning in BBH was balanced in Q3 2014: 7 funds opened new positions, 7 closed out, 23 added to existing stakes and 17 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $16.2M. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $1.42M sold.
- 59 institutional investors held VanEck Biotech ETF (BBH) as of Q3 2014, unchanged from Q2 2014.
- Funds reported $153M of VanEck Biotech ETF stock for Q3 2014, up 24% quarter-over-quarter.
- 7 funds opened new VanEck Biotech ETF positions in Q3 2014 and 7 closed out, a net change of 0 holders.
- The largest VanEck Biotech ETF buyer in Q3 2014 was Goldman Sachs, an estimated $16.2M added.
- The largest VanEck Biotech ETF seller in Q3 2014 was Virtu KCG Holdings, an estimated $1.42M sold.
Based on aggregated 13F filings for Q3 2014.